Gilead Sciences adds $11B to its U.S. investment plan, boosting manufacturing, R&D, and job creation. Read more here.

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies with smoked turkey and ham drew the crowd, but several people lingered for ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

Gilead is a vast pharmaceutical multinational. With a $175 billion market capitalisation nothing about the company is going to be small. There's a large HIV treatment arm which gives it a base in ...

Between greetings, Devine, executive director of the nonprofit group Hearts for the Homeless, commiserated with his ...

The global HIV antivirals market is experiencing a period of robust growth, driven by a combination of rising global awareness, remarkable advancements in pharmaceutical research, and the increasing ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.